Cataract - Pipeline Review, H2 2017 - Product Image

Cataract - Pipeline Review, H2 2017

  • ID: 4418989
  • Report
  • 43 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Genisphere LLC
  • Johnson & Johnson
  • Omeros Corp
  • Plex Pharmaceuticals Inc
  • MORE
Cataract - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H2 2017, provides an overview of the Cataract (Ophthalmology) pipeline landscape.

Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Genisphere LLC
  • Johnson & Johnson
  • Omeros Corp
  • Plex Pharmaceuticals Inc
  • MORE
Introduction

Cataract - Overview

Cataract - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cataract - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cataract - Companies Involved in Therapeutics Development

Acucela Inc

EyeGate Pharmaceuticals Inc

Genisphere LLC

Johnson & Johnson

Omeros Corp

Plex Pharmaceuticals Inc

Cataract - Drug Profiles

CAT-811 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GL-249 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanosterol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GPR161 for Central Nervous System Disorders, Oncology and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Ophthalmology and CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta-L Crystallin for Cataract and Presbyopia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cataract - Dormant Projects

Cataract - Discontinued Products

Cataract - Product Development Milestones

Featured News & Press Releases

Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts

May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To Progress Anti-Cataract Programme

Sep 04, 2011: New Drug Eyes Way To Beat Cataracts

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cataract, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Cataract - Pipeline by Acucela Inc, H2

Cataract - Pipeline by EyeGate Pharmaceuticals Inc, H2

Cataract - Pipeline by Genisphere LLC, H2

Cataract - Pipeline by Johnson & Johnson, H2

Cataract - Pipeline by Omeros Corp, H2

Cataract - Pipeline by Plex Pharmaceuticals Inc, H2

Cataract - Dormant Projects, H2

Cataract - Discontinued Products, H2

List of Figures

Number of Products under Development for Cataract, H2

Number of Products under Development by Companies, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acucela Inc
  • EyeGate Pharmaceuticals Inc
  • Genisphere LLC
  • Johnson & Johnson
  • Omeros Corp
  • Plex Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll